Jim Cramer questions Novo Nordisk A/S falling behind in weight loss drug market

From Yahoo Finance: 2025-06-25 12:20:00

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical giant struggling in the weight loss drug market. Shares down 15.7% YTD due to fears of Eli Lilly overtaking. Surprise CEO departure and CagriSema drug underperformance also contributing to losses. Activist investor Parvus taking stake, causing speculation on shakeup potential.

Jim Cramer questions Novo Nordisk A/S (NYSE:NVO) falling behind Eli Lilly in weight loss drug market. Elderly couple receiving insulin represents successful pharmaceutical products. Cramer suggests buying Eli Lilly given its consistent outperformance over Novo Nordisk. AI stocks seen as more promising investments with higher returns and limited downside risk.

Investors unsure about Novo Nordisk A/S (NYSE:NVO) potential, favoring AI stocks for better returns. Free report available for those interested in short-term AI stock benefiting from Trump tariffs. For more investment opportunities, check out the 20 Best AI Stocks to Buy Now and 30 Best Stocks to Buy Now According to Billionaires. No disclosures. This article first appeared on Insider Monkey.

Read more: “How Could They Be So Far Behind?,” Wonders Jim Cramer